21 results
8-K
EX-4.2
PMCB
PharmaCyte Biotech Inc
15 Nov 23
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
8:45pm
8-K
EX-4.1
PMCB
PharmaCyte Biotech Inc
15 Nov 23
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
8:45pm
8-K
EX-4.1
PMCB
PharmaCyte Biotech Inc
11 May 23
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000
8:30am
10-K
2022 FY
EX-4.2
PMCB
PharmaCyte Biotech Inc
Annual report
28 Jul 22
5:29pm
8-K
EX-4.1
PMCB
PharmaCyte Biotech Inc
23 Aug 21
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
6:01am
8-K
EX-4.2
yvn ur2jx2e4y9n3ctq
23 Aug 21
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
6:01am
8-K
EX-4.3
iooam3htbd z2mge
23 Aug 21
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
6:01am
8-K
EX-4.2
gj1zcdf
11 Aug 21
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
9:58pm
8-K
EX-4.1
9w0b76334lfkn 4dx
11 Aug 21
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
9:58pm
8-K
EX-4.3
bvif9d0tsu5fd6ue
11 Aug 21
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
9:58pm
8-K
EX-4.2
l9dmghd
12 Jan 16
Entry into a Material Definitive Agreement
12:00am
8-K
EX-4.1
7lg3i5
12 Jan 16
Entry into a Material Definitive Agreement
12:00am
S-3
EX-4.3
tv45hfzchkpj 6xw
17 Oct 14
Shelf registration
12:00am
S-3
EX-4.4
brv9s2d
17 Oct 14
Shelf registration
12:00am
8-K
EX-4.1
g8qi8b7rznb 7vvv3n
29 May 14
Nuvilex Enters into an At the Market Banking Agreement with Chardan Capital Markets
12:00am
8-K
EX-4.1
6xu9wxi0jcgak948o7qk
19 Feb 14
Nuvilex Announces $27 Million Funding Commitment with Institutional Investor to Advance Late Phase Clinical Trials
12:00am